top of page

TIMELINE

THE IDEA IS BORN
2013 - The laboratory of Drs. Mark Trifiro and Miltiadis Paliouras initiated a nanotherapeutics program that would exploit the properties of multi-walled carbon nanotubes (MWCNTS) as photo-thermal agents for the treatment of different cancer types.

​

PROOF-OF-PRINCIPLE
2014 - Drs. Trifiro and Paliouras, were awarded from the Canadian Institutes for Health Research – Proof of Principle Phase I grant ($150,000) to investigate the application of the nanotherapeutics platform on prostate cancer cells, targeting prostate specific membrane antigen (PSMA).  

​

PROOF-OF-PRINCIPLE
2015 – First in vitro targeted CNT experiments well under way

​

FIRST PUBLICATION
2016 - First publication illustrating the capacity of targeted MWCNTs to ablate cancer cells – THSR-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells. 

​

SECOND PUBLICATION
2017 - Second publication, highlighting the efficacy of the photothermal ablation of Prostate Cancer cells, with PSMA-targeted MWCNTs .

​

GNR, PATENTS, GRANTS, & COLLABORATIONS
2018 - The formation of Guzzo Nano Research Corp (GNR), to lead commercialization efforts to bring the BioNanofluid to clinical practice as a therapeutic modality for the treatment of cancer. 

USPTO Notice of Allowance of the patent. 
Drs Paliouras and Trifiro awarded a grant form the Cancer Research Society ($120,000) to evaluate the use of Trastuzumab as the targeting moiety to treat HER2 positive breast cancer cells. Trastuzumab is already in clinical use for treating HER2 positive breast cancer, however, the evaluation on the nanoformulation would aim to facilitate to regulatory process.
Drs. Trifiro and Paliouras, with the financial partnership of GNR were awarded a PSO grant from the Ministre de Innovation et Education ($183,000). This grant would assess the efficacy of the TSHR-targeted MWCNTs in an animal tumor model. 
GNR, in partnership with Neovaltech, were awarded a Bon d’Incubation grant ($38,850) form the Ministre de Innovation et Education.  This grant provided consultation services with Health Canada and allowed for the definition of the MWCNT nanoformulations as a medical device.  The designation of the nanoformulation would significantly determine the scope of the clinical trials moving forward.

​

GNR & THE NRC
2019 - GNR is granted a Certificate Award ($123,415) to assess the safety of the PSMA-BioNanofluid in small animals.  Of the 300+ animals injected with the anti-PSMA-MWCNTs, not a single serious adverse event was observed. 

​

R&D & GRANTS CONTINUES
2020 - GNR financially sponsored, a grant that was awarded to Drs. Trifiro and Paliouras from PRIMA Quebec ($462,502).  Part of the grant was also sponsored by, MITACS, The Jewish General Hospital Foundation and Institute TransMedTech.  The grant would explore the application of Raman Spectroscopy as an imaging modality to assess the concentration of the nanoformulation at the tumor site.  Knowing how much PSMA-targeted nanoformulation accumulates at the tumor site, will determine the power and duration of laser exposure, and thus ensure complete tumor ablation.

​

COVID-19 & RESERACH
2021 – Work earnestly under way assess the pre-clinical efficacy using a xenograft mouse model

​

GETTING EXPOSURE  & ANOTHER PATENT
2022 - GNR secures a license, with an assignment option, for the nanotheapeutic technology from McGill University. 
Nanotheapeutic technology pre-clincial efficacy of thyroid cancer targeting presented at NanoCanada – From Earth to Space. Edmonton, AB. 
CIPO Notice of Award of the patent

​

MORE EXPOSURE & ANOTHER TWO PUBLICATIONS
2023 - Review publication on the clinical application of Carbon Nanoparticles. Functionalized Carbon Nanoparticles as Theranostic Agents and their Future Clinical Utility in Oncology. MDPI Bioengineering (Basel). Publication of third research article demonstrating for the first time, pre-clinical efficacy of the targeted TSHR-BioNanofluid. Photothermal therapy of papillary thyroid cancer tumor xenografts with targeted thyroid stimulating hormone receptor antibody functionalized multiwalled carbon nanotubes.   BMC Cancer Nanotechnology. 

Nanotherapeutic technology for the treatment of HER2 breast cancer presented at: 8th Nano Today Conference, San Diego, CA

Initiated consulations with CERASP to identify a regulatory route forward for the BioNanofluid

​

DATA COLLECTION
2024 - Large scale efficacy and studies are planned to assess the PSMA-targeted nanoformulation for the treatment of prostate cancer.  This would will be done in collaboration with the laboratory of Dr. Trifiro and the NRC – Human Therapeutics Group (Ottawa) and a GNR sponsored grant through Axelys/MEI

​

MOVING TOWARDS CLINICAL TRIALS
2025+ - Compilation of data from small animal studies.  Move forward to large animal safety studies. Begin Health Canada interviews and application process.
 

bottom of page